Artificial Tears (Carboxymethylcellulose Sodium) Lubricant Eye Drops, 10 MG in 1 ml, 1/2 fl oz (1...
FDA Drug Recall #D-0920-2023 — Class II — January 30, 2023
Recall Summary
| Recall Number | D-0920-2023 |
| Classification | Class II — Moderate risk |
| Date Initiated | January 30, 2023 |
| Status | Ongoing |
| Voluntary | Voluntary: Firm initiated |
Recalling Firm
| Firm | Global Pharma Healthcare Private Limited |
| Location | Chennai, N/A |
| Product Type | Drugs |
| Quantity | 400,008 bottles total for all products |
Product Description
Artificial Tears (Carboxymethylcellulose Sodium) Lubricant Eye Drops, 10 MG in 1 ml, 1/2 fl oz (15 ml) bottle, Distributed by. EzriCare, LLC, Lakewood, NJ, NDC 79503-0101-15.
Reason for Recall
CGMP Deviations: All other lots of eye drops are being recalled due to CGMP Deviations because they were manufactured in the same facility under the same conditions as the lots found to be contaminated.
Distribution Pattern
Product was distributed to two distributors who further distributed Nationwide in the USA.
Lot / Code Information
Lot #: PCMH009, PCMH010, PCMH011, PCMH012, PCMH013, PCMH014, PCMH015, PCMH016, exp. date Nov-2023; PCMI001, PCMI002, PCMI003, PCMI004, PCMI006, PCMI 07, PCMI 008, Exp. date AUG-2024; PCMJ003, PCMJ007, PCMJ016, Exp. date MAR-2025
Other Recalls from Global Pharma Healthcare Private Limited
| Recall # | Classification | Product | Date |
|---|---|---|---|
| D-0488-2023 | Class I | Delsam Pharma's Artificial Eye Ointment (Minera... | Feb 24, 2023 |
| D-0919-2023 | Class I | Artificial Tears (Carboxymethylcellulose Sodium... | Jan 30, 2023 |
| D-0921-2023 | Class I | Delsam Pharma's ARTIFICIAL TEARS (Carboxymethyl... | Jan 30, 2023 |
| D-0922-2023 | Class II | Delsam Pharma's ARTIFICIAL TEARS (Carboxymethyl... | Jan 30, 2023 |
Frequently Asked Questions
cGMP stands for Current Good Manufacturing Practice — the FDA's regulations governing drug manufacturing quality. A cGMP recall means the company failed to follow required manufacturing standards. This could involve inadequate testing, poor environmental controls, documentation failures, or process deviations. cGMP recalls do not always mean the product is directly harmful — in many cases, quality records are insufficient to confirm the product meets specifications. However, the FDA requires a recall because without proper documentation, product quality cannot be assured. These are often Class II or Class III recalls.
Not necessarily. Many drug recalls are initiated because of quality system failures or test results that suggest a product might not meet specifications — even if no patients have reported harm. The FDA uses a precautionary approach: if there is reason to believe quality standards were not met, a recall is required regardless of whether adverse effects have been reported. Class I recalls typically involve a reasonable probability of harm; Class II recalls may cause temporary health issues; Class III recalls are for products unlikely to cause adverse health consequences but that still violate regulations.
Pharmacies typically receive recall notices directly from drug wholesalers and manufacturers within days of the recall being announced. Your pharmacist can look up whether any product in your prescription history matches a recalled lot number. For current recalls, the FDA publishes updates at FDA.gov/safety/recalls-market-withdrawals-safety-alerts and sends MedWatch email alerts for significant drug safety issues. You can sign up for MedWatch alerts at FDA.gov. Most major pharmacy chains also have their own recall notification systems that automatically alert pharmacists when a recalled product is in their inventory.
What Should You Do?
Stop using this medication if affected by this recall. Contact your pharmacist or prescribing doctor immediately for guidance. Do not flush medications — use a drug take-back program.